Dermacinrx Surgical Pharmapak (mupirocin/chlorhexidine glucon/dimethicone/silicone adhesive)

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

Moderate Interaction: Assess the risk to the patient and take action as needed.

Antimicrobial Topicals/Keratinocyte-Fibroblast Skin Tissue

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Antimicrobial topicals or dressings containing chlorhexidine, mafenide, or silver may decrease the viability of keratinocytes and fibroblasts used for wound healing in skin tissue replacement products.

CLINICAL EFFECTS: The use of antimicrobial topicals or dressings containing chlorhexidine, mafenide, or silver may disrupt the integrity of keratinocyte human skin substitutes and decrease the viability of keratinocytes and fibroblasts.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The use of antimicrobial topicals or dressings containing chlorhexidine, mafenide, or silver is not recommended.

DISCUSSION: Mafenide acetate has been shown to reduce keratinocyte viability and disrupt the integrity of tissue-engineered human skin substitutes. In vitro data suggest silver may decrease the viability of keratinocytes and human dermal fibroblasts. Chlorhexidine has been shown to be toxic to keratinocytes and human dermal fibroblasts.(1)

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

• Large open wound

• No disease contraindications

There is no enhanced messaging for this drug.

Rare or Very Rare

• Anaphylaxis
• Anaphylaxis
• Angioedema
• Angioedema
• Clostridioides difficile infection
• Dyspnea
• Facial edema
• Hypotension
• Tachycardia
• Urticaria
• Wheezing

More Frequent

• Headache disorder
• Nausea
• Skin rash

Less Frequent

• Dry skin
• Erythema
• Pruritus of skin
• Skin inflammation
• Skin swelling
• Stinging of skin
• Treatment site sequelae

Rare or Very Rare

• Acute abdominal pain
• Aphthous stomatitis
• Blistering skin
• Contact dermatitis
• Dizziness
• Erythema
• Pain
• Pruritus of skin
• Skin irritation
• Skin rash
• Urticaria

No enhanced messaging available.

No enhanced messaging available.

Data are insufficient to determine whether there is a drug-associated risk with use of mupirocin ointment for dermatologic use, mupirocin calcium cream for dermatologic use, or mupirocin calcium ointment for intranasal use in pregnant women. One manufacturer states that mupirocin ointment for dermatologic use should be used during pregnancy only if clearly needed.

Systemic absorption of mupirocin following topical application to intact skin is minimal. Although systemic absorption of mupirocin was reported to be negligible following intranasal application of mupirocin calcium ointment for intranasal use in adults, the dosage regimen used in this study did not mimic the recommended intranasal dosage.

Reproduction studies in rats or rabbits using subcutaneous mupirocin in dosages up to 22 or 43 times, respectively, the usual human topical dosage or up to 65 or 130 times, respectively, the usual human intranasal dosage have not revealed evidence of developmental toxicity.

It is not known whether systemically absorbed mupirocin is distributed into human milk, affects milk production, or affects the breast-fed infant. Because systemic absorption of mupirocin is minimal following topical application to skin and negligible following intranasal administration, the manufacturers state that mupirocin exposure in breast-feeding infants is unlikely.

The benefits of breast-feeding and the importance of mupirocin to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.

One manufacturer states that mupirocin ointment for dermatologic use should be used with caution in nursing women.

If a breast and/or nipple is being treated with mupirocin ointment for dermatologic use or mupirocin calcium cream for dermatologic use, the treated area should be thoroughly washed prior to breast-feeding to minimize oral exposure to the drug in the breast-feeding infant.

No enhanced messaging available.